skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Informa pharma logo

Pharma Intelligence is part of the Business Intelligence Division of Informa PLC

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

PharmaLogo
Search Icon Report storeRecommendationsProduct loginProductLogin
Global Search Configuration
Over the last few decades, there have been steady improvements in the prognosis of patients suffering from cystic fibrosis. This momentum is expected to continue, thanks to a new class of revolutionary CFTR-targeting therapies, which have the potential to increase life expectancy beyond the current average of 37 years.

Find out more about:

• The prevalence of cystic fibrosis in the US and five major EU markets

• The cystic fibrosis market value forecast from 2016 to 2025

• The compound annual growth rate in the cystic fibrosis market


This infographic will not be complimentary for long, so please make use of the opportunity to access the most cutting-edge information on cystic fibrosis.

Cystic Fibrosis

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Request a free demo

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907
  • Japan            : +81 3-6273-4257

Or email us your inquiry, so we can provide you the best possible customer service:
pharma@informa.com
General enquiry

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now:

Shop now